Implementing drug regulator’s changes doesn’t put patients first
The PMPRB regulatory changes set aggressive price ceilings for some new therapies, especially those involving rare disorders, that make it almost guaranteed that these therapies will not be brought to the Canadian market.
The federal government is currently on track to implement regulatory changes to the Patented Medicines Prices Review Board on July 1. These changes will negatively impact the lives of Canadians who depend on medications.
The pro...
SPONSORED CONTENT
Get Weekend Point of View Newsletter
A round up of the past week’s opinion writers and columnists on Saturdays and Sundays.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
